MicroRNA Signature of Primary Pigmented Nodular Adrenocortical Disease: Clinical Correlations and Regulation of Wnt Signaling

被引:66
|
作者
Iliopoulos, Dimitrios [2 ]
Bimpaki, Eirini I. [1 ]
Nesterova, Maria [1 ]
Stratakis, Constantine A. [1 ]
机构
[1] NICHHD, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, NIH, Bethesda, MD 20892 USA
[2] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
关键词
CARNEY COMPLEX; EXPRESSION; TUMORS; HYPERPLASIAS; PATHWAYS; MUTATION; GENES;
D O I
10.1158/0008-5472.CAN-09-0155
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs comprise a novel group of gene regulators implicated in the development of different types of cancer; however, their role in primary pigmented nodular adrenocortical disease (PPNAD) has not been investigated. PPNAD is a bilateral adrenal hyperplasia often associated with Carney complex, a multiple neoplasia syndrome; both disorders are caused by protein kinase A (PKA) regulatory subunit type 1A (PRKARIA)-inactivating mutations. We identified a 44-microRNA gene signature of PPNAD after comparing PPNAD with normal adrenal samples. Specifically, 33 microRNAs were up-regulated and 11 down-regulated in PPNAD relative to normal tissues. These results were validated by stem loop real-time PCR analysis. Comparison of microRNA microarray data with clinicopathologic variables revealed a negative correlation (r = -0.9499) between let-7b expression and cortisol levels in patients with PPNAD. Integration of microRNA microarray with serial analysis of gene expression data together with bioinformatic algorithm predictions revealed nine microRNA-gene target pairs with a potential role in adrenal pathogenesis. Using a PPNAD cell line, we showed that miR-449 was up-regulated and identified its direct target, WNT1-inducible signaling pathway protein 2 (WISP2); in addition, pharmacologic inhibition of PKA resulted in the up-regulation of miR-449 leading to the suppression of WISP2. Overall, we investigated, for the first time, the microRNA profile and its clinical significance in PPNAD; these data also suggest that PKA, via microRNA regulation, affects the Writ signaling pathway, which through expression and clinical studies is suspected to be a primary mediator of PRKAR1A-related tumorigenesis. [Cancer Res 2009;69(8):3278-82]
引用
收藏
页码:3278 / 3282
页数:5
相关论文
共 50 条
  • [1] Primary pigmented nodular adrenocortical disease
    Ngow, Harris Abdullah
    Khairina, Wan Mohd Nowalid Wan
    ENDOKRYNOLOGIA POLSKA, 2011, 62 (03) : 268 - 270
  • [2] Treatment of Primary Pigmented Nodular Adrenocortical Disease
    Liu, Xinming
    Zhang, Siwen
    Guo, Yunran
    Gang, Xiaokun
    Wang, Guixia
    HORMONE AND METABOLIC RESEARCH, 2022, 54 (11) : 721 - 730
  • [3] Primary pigmented nodular adrenocortical disease (PPNAD): single centre experience
    Memon, Saba Samad
    Thakkar, Kunal
    Patil, Virendra
    Jadhav, Swati
    Lila, Anurag R.
    Fernandes, Gwendolyn
    Bandgar, Tushar R.
    Shah, Nalini S.
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2019, 32 (04) : 391 - 397
  • [4] Primary pigmented nodular adrenocortical disease and Cushing's syndrome
    Horvath, Anelia
    Stratakis, Constantine
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 (08) : 1238 - 1244
  • [5] Primary pigmented nodular adrenocortical disease: a case report in a 7-year-old girl
    Leka, Sofia
    Kousta, Eleni
    Anyfandakis, Konstantinos
    Dolianiti, Maria
    Vakaki, Marina
    Linos, Dimitrios
    Chrousos, George P.
    Papathanasiou, Asteroula
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2011, 24 (3-4) : 197 - 202
  • [6] An unusual presentation of Carney complex with diffuse primary pigmented nodular adrenocortical disease on one adrenal gland and a nonpigmented adrenocortical adenoma and focal primary pigmented nodular adrenocortical disease on the other
    Tung, Shih-Chen
    Hwang, Daw-Yang
    Yang, Joseph W.
    Chen, Wei-Jen
    Lee, Chien-Te
    ENDOCRINE JOURNAL, 2012, 59 (09) : 823 - 830
  • [7] PRKAR1A mutations in primary pigmented nodular adrenocortical disease
    Cazabat L.
    Ragazzon B.
    Groussin L.
    Bertherat J.
    Pituitary, 2006, 9 (3) : 211 - 219
  • [8] Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease
    Stratakis, CA
    Sarlis, N
    Kirschner, LS
    Carney, JA
    Doppman, JL
    Nieman, LK
    Chrousos, GP
    Papanicolaou, DA
    ANNALS OF INTERNAL MEDICINE, 1999, 131 (08) : 585 - +
  • [9] Does Somatostatin Have a Role in the Regulation of Cortisol Secretion in Primary Pigmented Nodular Adrenocortical Disease (PPNAD)? A Clinical and in Vitro Investigation
    Bram, Zakariae
    Xekouki, Paraskevi
    Louiset, Estelle
    Keil, Meg F.
    Avgeropoulos, Dimitrios
    Giatzakis, Christoforos
    Nesterova, Maria
    Sinaii, Ninet
    Hofland, Leo J.
    Cherqaoui, Rabia
    Lefebvre, Herve
    Stratakis, Constantine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (05) : E891 - E901
  • [10] Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome
    Hofland, Johannes
    de Herder, Wouter W.
    Derks, Lieke
    Hofland, Leo J.
    van Koetsveld, Peter M.
    de Krijger, Ronald R.
    van Nederveen, Francien H.
    Horvath, Anelia
    Stratakis, Constantine A.
    de Jong, Frank H.
    Feelders, Richard A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (01) : 67 - 74